Abstract
Background: With the development of new biomarkers and therapeutic targets in solid tumor oncology there comes a need for expanded Next Generation Sequencing (NGS) panels. Laboratories with limited bioinformatics resources can mitigate this complexity by using third party bioinformatics platforms. This study assesses the accuracy of Pierian CGW and SOPHiA DDM (SOPHiA GENETICS) variant calling using the Horizon HD789 Control material sequenced using the llumina TruSight Tumor 170 (TS170) panel.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
